10.3 Approach to the Bleeding Neonate

Bedside Safety Message

Four rules — read before any transfusion decision

Treat active bleeding first, but obtain key samples before blood products when this does not delay resuscitation.
Do not transfuse FFP or platelets only to "normalize" abnormal neonatal laboratory values in a non-bleeding infant.
A well-appearing neonate with severe isolated thrombocytopenia should be treated as possible NAIT until proven otherwise.
If hemophilia is possible, avoid IM injections and invasive procedures until hematology guidance is obtained.

1. Purpose and Core Principle

This chapter provides a practical NICU approach to bleeding, bruising, oozing, pulmonary hemorrhage, gastrointestinal bleeding, suspected intracranial hemorrhage, coagulopathy, thrombocytopenia, DIC, vitamin K deficiency bleeding, and inherited coagulation disorders. It is written for bedside stabilization and should be used together with local blood-bank, hematology, neurosurgery, and transfusion-medicine policies.

Core principle

Classify the infant as stable vs. unstable, well vs. sick, platelet problem vs. coagulation-factor problem, and isolated bleeding vs. systemic disease.

2. Immediate Bedside Algorithm

Stabilize airway, breathing, circulation, temperature, glucose, and perfusion. Apply direct pressure to accessible bleeding sites and stop unnecessary blood sampling.
Call for help early if bleeding is major: neonatologist, bedside nurse lead, blood bank, hematology, surgery, neurosurgery, or transport team as clinically indicated.
Before giving products, if safe: send CBC with platelet count and smear, PT/INR, aPTT, fibrinogen, D-dimer/FDP if DIC is possible, blood gas/lactate, glucose, electrolytes, liver panel, bilirubin, type and screen/crossmatch, blood culture if ill, and targeted tests such as factor assays or platelet antibody testing.
If unstable or actively bleeding, do not wait for all results. Begin product-specific support guided by the likely defect: PRBC for hemorrhagic anemia/shock, platelets for severe thrombocytopenia with bleeding, FFP for bleeding with prolonged PT/aPTT, cryoprecipitate for bleeding with low fibrinogen, vitamin K for suspected VKDB, and factor concentrate when a specific factor deficiency is known.
Reassess after each intervention: perfusion, bleeding rate, respiratory status, hemoglobin/hematocrit, platelet count, PT/INR/aPTT, fibrinogen, calcium, potassium, temperature, and acid-base status.
After stabilization, determine the cause and document a prevention plan for future procedures, circumcision, line placement, surgery, discharge counseling, and future pregnancies if immune disease is suspected.

3. Definitions Used at Bedside

Term	Practical NICU Definition
Major bleeding	Fresh bleeding from upper GI tract, stoma, macroscopic hematuria, acute fresh ETT bleeding, grade 3–4 IVH, frank rectal blood, or any bleeding with hypotension, hypovolemia, ventilatory deterioration, volume bolus, or PRBC requirement in the same 24 hours.
Minor bleeding	Oozing from skin, umbilicus, stoma edge, surgical scar, mucosa, small old blood from ETT/feeding tube, or localized germinal matrix/subependymal hemorrhage without systemic instability.
Clinically important coagulopathy	Bleeding or high-risk procedure plus PT/INR or aPTT clearly prolonged for gestational/postnatal age, or low fibrinogen, particularly in sepsis, NEC, hypoxia-ischemia, liver failure, metabolic disease, or therapeutic hypothermia.
Severe thrombocytopenia	Platelet count below 50 × 10⁹/L; in an otherwise well term neonate, consider NAIT until another cause is proven.

4. Why Neonatal Bleeding Is Different

The newborn hemostatic system is developmentally immature but usually balanced. Vitamin K-dependent factors and contact factors are lower than adult values at birth; natural anticoagulants (antithrombin, protein C, protein S) are also lower; and normal values vary by gestational and postnatal age. This means a prolonged PT or aPTT is not automatically a bleeding indication, and laboratory values must be interpreted with the clinical picture.

Practical pitfall: treat the baby, not the number

In a non-bleeding infant, prophylactic correction of abnormal coagulation tests with FFP has not shown benefit and may increase donor exposure, volume load, and transfusion-related complications.

5. Initial Assessment: Find the Pattern

Clinical-Lab Pattern	Likely Causes	Action
Well baby + normal platelets + normal PT/aPTT	Local trauma, anatomic lesion, swallowed maternal blood, qualitative platelet disorder, factor XIII deficiency.	Inspect site, Apt test if GI blood may be maternal, consider factor XIII if delayed bleeding with normal PT/aPTT.
Well baby + isolated low platelets	NAIT, maternal ITP/SLE, drug-related antibodies, occult infection, thrombosis, marrow disease.	Repeat venous platelet count, review maternal platelets/drugs, cranial ultrasound if severe, consult hematology/blood bank if NAIT possible.
Well baby + isolated prolonged aPTT	Hemophilia A/B or other intrinsic pathway factor deficiency.	Avoid IM injections/procedures, send factor VIII/IX and hematology consult; use factor concentrate if available for bleeding.
Well baby + prolonged PT and aPTT with normal platelets	Vitamin K deficiency bleeding, liver synthetic dysfunction, rare factor deficiency.	Ask about vitamin K administration, maternal warfarin/antiepileptics/cholestasis; give vitamin K after labs; FFP if active bleeding.
Sick baby + low platelets and prolonged PT/aPTT	DIC from sepsis, NEC, asphyxia/HIE, severe RDS/MAS, shock, liver failure, metabolic disease (e.g., galactosemia).	Treat underlying cause urgently; broad labs/cultures; product support only when bleeding, severe thrombocytopenia, procedure, or low fibrinogen.
Bleeding with hepatosplenomegaly / jaundice / coagulopathy	Liver failure, cholestasis, galactosemia, tyrosinemia, HSV, metabolic liver disease.	LFTs, bilirubin fractionation, glucose, ammonia/lactate, metabolic/infectious testing; genetics/metabolic and liver consultation.

6. When to Order Coagulation Studies

Do not screen every well newborn or preterm infant solely because coagulation values may be developmentally prolonged. Order PT/INR, aPTT, and fibrinogen when there is:

Active or clinically concerning bleeding
High DIC risk (sepsis, NEC, asphyxia, shock)
Surgery or tissue biopsy with a bleeding history
Therapeutic hypothermia
Thrombocytopenia requiring evaluation
Major illness, significant liver dysfunction, or conjugated jaundice
Metabolic disease with potential liver involvement
Family history of an inherited bleeding disorder

Sampling technique matters

Use a free-flowing venous or arterial sample, avoid heparin contamination, fill the citrate tube correctly, and repeat clotted or suspicious samples before acting on unexpected results.

7. Product Selection: Match the Product to the Problem

Product	Use When	Bedside Notes
Vitamin K	Prevention of VKDB for all newborns; treatment when VKDB is possible.	Prophylaxis: 1 mg IM for infants >1500 g within 6 hours; 0.3 mg IM for ≤1500 g. If active bleeding and not yet given, give therapeutic vitamin K after coagulation labs. Avoid IM route if hemophilia is strongly suspected until discussed with hematology.
PRBC	Hemorrhagic shock, acute blood loss, symptomatic anemia, major bleeding with falling hemoglobin.	Emergency support may require 10 mL/kg rapidly with reassessment; stable transfusion commonly 10–20 mL/kg over 3–4 hours. Monitor potassium, calcium, temperature, glucose, and volume status during large or rapid transfusion.
Platelets	Thrombocytopenia with bleeding, major bleeding/surgery, invasive procedure, suspected NAIT, or very low count per threshold table.	Restrictive thresholds preferred (see Section 8). In NAIT: do not wait for confirmation — transfuse and obtain HPA-compatible or washed/irradiated maternal platelets when available.
FFP	Bleeding with prolonged PT/aPTT due to DIC, liver failure, VKDB, dilutional coagulopathy, or when factor concentrate is unavailable.	Typical dose 10–15 mL/kg over 30–60 minutes (up to 20 mL/kg in severe cases). Do not use for volume expansion or isolated abnormal coagulation tests without bleeding. Recheck PT/INR/aPTT after treatment.
Cryoprecipitate	Bleeding or high-risk hemorrhage with low fibrinogen, DIC, trauma, surgical bleeding, or factor XIII deficiency when specific products are unavailable.	Dose 5–10 mL/kg. Often used when fibrinogen is <100 mg/dL (<0.8–1.0 g/L with bleeding, per local reference). Provides concentrated fibrinogen with less volume than FFP.
Factor concentrate	Known hemophilia A/B, factor VII deficiency, factor XIII deficiency, or other defined disorder.	Preferred over FFP when available. Discuss dosing and monitoring with pediatric hematology.

8. Platelet Transfusion Strategy

What is actually normal in a newborn (Baylor Ed. 33)

The adult range of 150,000–450,000/µL has historically been applied to newborns, but healthy preterm and term infants sit well outside it: 104,000 to 750,000/µL are the 5th and 95th percentiles. The count then rises in postnatal life in a sinusoidal pattern with two peaks, at 2–3 weeks and 6–7 weeks.
Why the coagulation screen looks abnormal in a well baby: hemostatic proteins are synthesized solely by the fetus and do not cross the placenta. The vitamin-K-dependent factors (II, VII, IX, X) start low from reduced hepatic stores, limited placental vitamin K transfer, low vitamin K in breast milk and a sterile gut; those and the contact factors (XI, XII) run about 50% below adult values in term infants and lower still in preterm infants. Antithrombin, protein C and protein S are also reduced, so fibrinolytic capacity falls too. The counterbalance is why healthy infants rarely bleed — and values reach near-adult levels by 6 months.
A dose of platelets raises the count less than the textbook says: 5–10 mL/kg of whole-blood-derived platelets should lift the count by 50–100 × 10⁹/L, but in neonates the actual rise is much smaller because the cause is usually destructive — DIC, NAIT, sepsis. Treat the underlying disorder aggressively alongside the transfusion.
Mild hemophilia B is genuinely hard to diagnose in the newborn period because factor IX is physiologically low after birth. If hemophilia is suspected: avoid invasive monitoring, defer intramuscular vitamin K until it is excluded, and give fresh frozen plasma 15–25 mL/kg if bleeding is significant.

Clinical state	Platelets	PT	PTT	Likely diagnosis (Baylor Table 8-1)
Well — the bleeding is an isolated problem	Normal	Normal	Normal	Local factors (trauma, anatomic abnormality), qualitative platelet defect, factor XIII deficiency
	Normal	Normal or ↑	↑	Hereditary clotting factor deficiency
	Normal	↑	↑	Haemorrhagic disease of the newborn (vitamin K deficiency)
	↓	Normal	Normal	Immune thrombocytopenia, occult infection, thrombosis, marrow infiltration or hypoplasia
Sick — the bleeding is part of a systemic disorder	Normal	Normal	Normal	Compromised vascular integrity — hypoxia, prematurity, acidosis, hyperosmolarity
	Normal	↑	↑	Liver disease
	↓	Normal	Normal	Platelet consumption — infection, NEC, renal vein thrombosis
	↓	↑	↑	Disseminated intravascular coagulation

A restrictive platelet strategy is favored for most preterm infants. Higher prophylactic thresholds did not reduce major bleeding and were associated with worse outcomes in the PlaNeT-2 trial. The exception is a neonate with major bleeding, major surgery, or suspected NAIT, where higher target counts may be justified.

Situation	Practical Platelet Approach
Stable, no bleeding	Usually transfuse only if <25–30 × 10⁹/L; trend and clinical context matter.
Clinically unstable, coagulopathy, <1000 g and <7 days, minor bleeding, planned invasive procedure, exchange transfusion, PDA NSAID treatment, or count falling quickly	Consider transfusion if <50 × 10⁹/L.
Major bleeding, neurosurgery, major surgery, pulmonary/GI/ICH bleeding	Target ≥100 × 10⁹/L until bleeding is controlled or per hematology/surgery plan.
Suspected NAIT	Do not wait for confirmatory testing. Transfuse platelets promptly if severe; use HPA-compatible or washed/irradiated maternal platelets when available, but give random donor platelets while waiting. Obtain cranial ultrasound if platelet count <50 × 10⁹/L.

9. Condition-Specific Management

Condition	Action-Oriented Management
Vitamin K deficiency bleeding (VKDB)	Suspect when vitamin K was not given or status is uncertain, exclusive breastfeeding, cholestasis/malabsorption, or maternal warfarin/enzyme-inducing anticonvulsants. Send coagulation labs first if safe, give vitamin K, and use FFP for active serious bleeding while vitamin K takes effect (response may take 4–6 hours).
Hemophilia or inherited factor deficiency	Suspect in male infant, family history, procedure-site oozing, cephalohematoma/subgaleal bleed, ICH, or isolated prolonged aPTT. Avoid circumcision, IM injections, arterial sticks, and unnecessary invasive lines until a plan exists. Use factor concentrate when available; FFP is a bridge only if factor is unavailable and bleeding is significant.
DIC	Think: sepsis, NEC, asphyxia/HIE, shock, severe liver dysfunction, RDS/MAS, or metabolic disease. Treat the trigger. Support with platelets/FFP/cryo only when there is bleeding, severe thrombocytopenia, low fibrinogen, or procedure risk.
NAIT (Neonatal Alloimmune Thrombocytopenia)	Severe thrombocytopenia in a well term neonate is NAIT until proven otherwise. Consult hematology and blood bank urgently; obtain platelet count trend; send maternal/paternal platelet antigen testing and maternal antiplatelet antibody testing; screen for ICH when platelets are <50 × 10⁹/L.
Liver / metabolic disease	Bleeding with conjugated jaundice, hypoglycemia, hepatomegaly, coagulopathy, or E. coli sepsis should trigger evaluation for galactosemia, tyrosinemia, viral infection, and liver failure. Give vitamin K and manage synthetic failure with metabolic/GI specialist input.

10. Practical Monitoring After Blood Products

Platelets: document indication, product type, dose, and timing; check a post-transfusion platelet count within the local policy window. In NAIT, a 20–60-minute count helps determine response because random donor platelets may have a short effect.
FFP or cryoprecipitate: repeat PT/INR/aPTT and fibrinogen after treatment if bleeding continues or more procedures are planned; do not repeat products just to correct numbers in a non-bleeding infant.
PRBC or massive bleeding: monitor calcium, potassium, temperature, glucose, acid-base status, lactate, urine output, and signs of volume overload or pulmonary deterioration.
Any transfusion reaction: stop transfusion, maintain IV access with normal saline, assess airway/breathing/circulation, notify blood bank, and follow institutional transfusion-reaction protocol.

11. Documentation and Family Communication

Document the bleeding site, severity, hemodynamic impact, suspected mechanism, pre-product labs, product dose/rate, response, and planned recheck labs.
Discuss blood products with parents whenever the situation allows; life-threatening bleeding should be treated immediately with documentation afterward.
Before discharge, families of infants with NAIT, hemophilia, unexplained severe thrombocytopenia, or VKDB should receive clear follow-up instructions and specialist appointments.
For suspected immune thrombocytopenia or inherited disorders, include recurrence-risk counseling and future pregnancy planning in the discharge handoff.

12. Teaching Points for Fellows and Residents

Key conceptual anchors

A sick bleeding neonate usually has acquired disease until proven otherwise; a well bleeding neonate often has immune, inherited, or local causes.
A normal PT/aPTT does not exclude platelet dysfunction or factor XIII deficiency.
FFP is not a hemostatic "vitamin"; it is a blood product for bleeding with factor deficiency or DIC/liver-failure patterns — not for treating abnormal lab values alone.
Severe isolated thrombocytopenia in a well term baby is a hematology emergency because NAIT can cause intracranial hemorrhage at any moment.
In suspected hemophilia, the first management step is often avoidance: no IM injections, no circumcision, no unnecessary arterial puncture, and no traumatic procedures until a plan exists.

13. Source-Difference Notes

Source	How It Shaped This Chapter
Baylor 2025–2026	Structured bleeding-definition approach, differential diagnosis by platelet/PT/aPTT pattern, product-specific doses, and support for conservative platelet transfusion.
West Midlands 2025–2028	Strongly emphasizes not routinely screening coagulation in well infants, avoiding FFP for abnormal labs alone, careful sampling, and restrictive platelet thresholds with NAIT-specific escalation.
Belize 2018–2021	Practical neonatal transfusion details including product handling, platelet/FFP doses, donor-exposure reduction, CMV/leukoreduced/irradiated products, and transfusion-reaction monitoring.
Updated evidence	AAP vitamin K prophylaxis recommendations (2022) and PlaNeT-2 neonatal platelet trial (Curley et al. NEJM 2019) support IM vitamin K for prevention and a restrictive platelet strategy in non-bleeding preterm infants.

Key Takeaways — Chapter 10.3

Classify first: stable vs. unstable, well vs. sick, platelet problem vs. factor problem, isolated vs. systemic — this drives the entire management approach.
Send key labs before products when it is safe to do so; do not let laboratory results delay resuscitation of an unstable bleeding neonate.
Never transfuse FFP or platelets to correct an abnormal number in a non-bleeding infant — treat the patient, not the test.
Restrictive platelet strategy: <25–30 × 10⁹/L if stable; <50 × 10⁹/L if unstable, coagulopathic, VLBW first week, or procedure pending; ≥100 × 10⁹/L target for major bleeding or surgery.
NAIT: severe thrombocytopenia in a well term baby is NAIT until proven otherwise — do not wait for maternal antibody results before transfusing if platelets are critically low.
Hemophilia: the first step is avoidance — no IM, no circumcision, no unnecessary arterial access — until hematology has reviewed the case.
VKDB: give vitamin K first (after labs if safe); use FFP as a bridge for active serious bleeding while vitamin K is taking effect.
DIC: treat the underlying cause — sepsis, NEC, asphyxia. Product support is supportive, not curative.

References and Key Source Material

Baylor College of Medicine. Guidelines for Acute Care of the Neonate, Edition 33, 2025–2026. Section 8: Hematology, Chapter 8.1: Approach to the Bleeding Neonate.
West Midlands Neonatal Operational Delivery Network. Neonatal Guidelines 2025–2028. Coagulopathy, Thrombocytopenia, and Vitamin K guidelines.
Belize Ministry of Health. Neonatal Clinical Practice Guidelines 2018–2021. Blood Components Transfusion section.
Hand I, Noble L, Abrams SA. Vitamin K and the Newborn Infant. Pediatrics. 2022;149(3):e2021056036.
Curley A, Stanworth SJ, Willoughby K, et al. Randomized Trial of Platelet-Transfusion Thresholds in Neonates (PlaNeT-2). N Engl J Med. 2019;380:242–251.
British Society for Haematology. Guidelines on transfusion for fetuses, neonates and older children, addendum August 2020.
Royal Children's Hospital Melbourne. Blood Transfusion: Neonatal transfusions. Updated online guideline.
NHSGGC. Neonatal transfusion guideline. Updated online guideline.

Quality note

This chapter is an educational guideline and does not replace bedside judgment. Product availability, component specifications, factor concentrate access, and transfusion thresholds must be aligned with local hematology and transfusion-medicine policy.